IART Earnings Date: Feb 25, 2027 (Estimated) — Integra LifeSciences Holdings Corporation
NASDAQ · Healthcare · Medical Devices
Updated
When is IART's next earnings date?
Integra LifeSciences Holdings Corporation (IART) is expected to report Q4 2026 earnings on Thursday, February 25, 2027 at 6:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $0.80 on revenue of $447.5M.
How did IART do in its last earnings report?
In its most recent report on Oct 21, 2026 (Q3 2026), Integra LifeSciences Holdings Corporation posted EPS of $0.59 versus the $0.56 estimate, a beat of 5.4%. Revenue was $411.2M against a $416.3M estimate. The stock's 1-day post-earnings move was -11.2%.
How much does IART stock move after earnings?
IART beat EPS estimates in 8 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 15.1% (up or down) in the day after earnings.
About Integra LifeSciences Holdings Corporation
Integra LifeSciences Holdings Corporation is a medical technology company focused on the creation, production, and global distribution of advanced surgical implants and instruments. These products are utilized across various medical fields, including neurosurgery, limb reconstruction, and general surgical procedures. The company operates through two primary business segments: Codman Specialty Surgical and Tissue Technologies. The Codman Specialty Surgical division offers a comprehensive range of neurosurgical and neuro-critical care products. This includes specialized equipment for tissue ablation, dural repair solutions, cerebral spinal fluid management systems, intracranial monitoring tools, and cranial stabilization devices. Additionally, this segment provides surgical headlamps, various instrumentation, and supports these offerings with asset management software, technical assistance, and after-market services. Integra also supplies an extensive catalog of approximately 40,000 surgical instrument designs, along with a wide selection of surgical and lighting products. Its clientele spans hospitals, surgical centers, and extends to dental, podiatry, and veterinary practices. The Tissue Technologies segment specializes in innovative regenerative technology products for the treatment of both acute and chronic wounds. It further provides surgical tissue repair solutions for a multitude of applications, such as hernia repair, peripheral nerve protection and regeneration, and tendon reconstruction. This encompasses a broad array of offerings for skin and wound repair, plastic and reconstructive surgery products, bone grafting materials, and specialized nerve and tendon repair products. Integra LifeSciences distributes its diverse product portfolio internationally, reaching markets throughout the United States, Europe, Asia Pacific, and other global regions. Distribution is managed directly through its dedicated sales forces and various other channels, serving a wide array of healthcare entities including hospitals, integrated health networks, group purchasing organizations, individual clinicians, surgery centers, and other healthcare providers. Founded in 1989, Integra LifeSciences Holdings Corporation is headquartered in Princeton, New Jersey.
🤖 AI Earnings Analysis
Integra’s medical-device results were mixed: EPS beat by $0.03 at $0.59, but revenue of $411M missed estimates by $5M. The stated $1.6B–$1.7B revenue outlook offers little reassurance amid weak operating income.
AI-generated summary — powered by BigEarnings.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-21 | Q3 2026 | 0.56 | 0.59 | +5.36% | $411.2M | ✅ Beat | -11.18% | -10.05% | — |
| 2026-07-29 | Q2 2026 | 0.48 | 0.56 | +16.67% | $418.8M | ✅ Beat | -16.55% | -9.41% | -14.57% |
| 2026-05-05 | Q1 2026 | 0.41 | 0.54 | +31.71% | $391.9M | ✅ Beat | +24.13% | +31.17% | +51.17% |
| 2026-02-26 | Q4 2025 | 0.80 | 0.83 | +3.75% | $434.9M | ✅ Beat | -2.24% | -10.35% | -19.07% |
| 2025-10-30 | Q3 2025 | 0.43 | 0.54 | +25.58% | $402.1M | ✅ Beat | -23.46% | -26.12% | -14.97% |
| 2025-07-31 | Q2 2025 | 0.43 | 0.45 | +4.65% | $415.6M | ✅ Beat | +6.22% | +0.00% | +19.97% |
| 2025-02-25 | Q4 2024 | 0.86 | 0.97 | +12.79% | $442.6M | ✅ Beat | +12.11% | +1.95% | +0.59% |
| 2024-11-04 | Q3 2024 | 0.39 | 0.41 | +5.13% | $380.8M | ✅ Beat | +25.10% | +28.53% | +27.75% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q4 FY25 · $434.9M total
| Segment | Share | Revenue | YoY | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 |
|---|---|---|---|---|---|---|---|
| Codman Specialty Surgical | 74.3% | $323.3M | +2.7% | $301.8M | $270.8M | $314.7M | $280.7M |
| Tissue Technologies | 25.7% | $111.6M | -12.8% | $116.4M | $110.1M | $128.0M | $102.0M |
By region
Q3 FY26 · $411.2M total
| Segment | Share | Revenue | YoY | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|---|---|---|---|
| UNITED STATES | 72.8% | $299.3M | +1.2% | $282.2M | $306.3M | $295.8M | $320.4M |
| Asia Pacific | 11.7% | $47.9M | +12.3% | $45.1M | $47.7M | $42.7M | $53.7M |
| Europe | 10.3% | $42.3M | -1.4% | $35.3M | $42.6M | $42.9M | $41.9M |
| Rest Of The World | 5.3% | $21.6M | +4.9% | $20.0M | $19.0M | $20.6M | $19.0M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.